SEHK:1952Biotechs
Everest Medicines MT1013 Deal Expands Renal Pipeline As Shares Lag Targets
Everest Medicines (SEHK:1952) has signed an exclusive license agreement to commercialize MT1013 for secondary hyperparathyroidism in China and the broader Asia Pacific region.
MT1013 is entering Phase III trials, with development expenses covered by Everest Medicines' partner under the deal.
The agreement expands the company’s renal pipeline and commercial portfolio, targeting unmet medical needs in kidney related complications.
Everest Medicines, trading at HK$38.86, has seen mixed share...